Clinical Trial Update: Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 neoadjuvant study evaluating carboplatin, eribulin, and trastuzumab in operable HER2-positive breast cancer was terminated; results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Eribulin (eribulin mesilate)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Vector Oncology | Conditions: HER-2 Positive Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-08-28